北京大学医学部机构知识库
Advanced  
IR@PKUHSC  > 北京大学第二临床医学院  > 胸外科  > 期刊论文
学科主题: 临床医学
题名:
Comparison of Epidermal Growth Factor Receptor Mutation Statuses in Tissue and Plasma in Stage I-IV Non-Small Cell Lung Cancer Patients
作者: Zhao, Xiao1; Han, Ru-Bing1; Zhao, Jing1; Wang, Jun2; Yang, Fan2; Zhong, Wei1; Zhang, Li1; Li, Long-Yun1; Wang, Meng-Zhao1
关键词: Epidermal growth factor receptor ; Mutation ; Non-small cell lung cancer ; Plasma
刊名: RESPIRATION
发表日期: 2013
DOI: 10.1159/000338790
卷: 85, 期:2, 页:119-125
收录类别: SCI
文章类型: Article
WOS标题词: Science & Technology
类目[WOS]: Respiratory System
研究领域[WOS]: Respiratory System
关键词[WOS]: EGFR MUTATIONS ; CIRCULATING DNA ; GEFITINIB ; SERUM ; TUMOR ; CHEMOTHERAPY ; PREDICTOR ; ERLOTINIB ; ASSAY ; GENE
英文摘要:

Background: Epidermal growth factor receptor (EGFR) mutations play essential roles in the treatment of non-small cell lung cancer (NSCLC) patients using EGFR tyrosine kinase inhibitors. Detection of EGFR mutations in blood cell-free DNA (cfDNA) seems promising. However, the mutation status in the plasma/serum is not always consistent with that in the tissues. Objectives: The aims of this study were to compare the mutation statuses in plasma to those in tissues and thus to determine the specific subgroups of NSCLC patients who may be the best candidates for EGFR mutation analyses using blood cfDNA. Methods: A total of 111 pairs of tissue and plasma samples were collected. Mutant-enriched PCR and sequencing analyses were performed to detect EGFR exon 19 deletions and exon 21 L858R mutations. Results: Mutations were discovered in 43.2% (48/111) of the patients. The overall rate of consistency of the EGFR mutation statuses for the 111 paired plasma and tissue samples was 71.2% (79/111). The sensitivity and specificity rates of detecting EGFR mutations in the plasma were 35.6% (16/45) and 95.5% (63/66), respectively. The disease stage and tumor differentiation subgroups showed significantly different detection sensitivities; the sensitivity was 10% in early-stage patients and 56% in advanced-stage patients (p = 0.0014). For patients with poorly differentiated tumors, the sensitivity was 77.8%, which was significantly different from those with highly differentiated (20%; p = 0.0230) and moderately differentiated tumors (19%; p = 0.0042). Conclusion: Blood analyses for EGFR mutations may be effectively used in advanced-stage patients or patients with poorly differentiated tumors. Copyright (C) 2012 S. Karger AG, Basel

语种: 英语
项目资助者: Peking Union Medical College Hospital
WOS记录号: WOS:000316997500006
Citation statistics:
内容类型: 期刊论文
URI标识: http://ir.bjmu.edu.cn/handle/400002259/57186
Appears in Collections:北京大学第二临床医学院_胸外科_期刊论文

Files in This Item:

There are no files associated with this item.


作者单位: 1.Chinese Acad Med Sci, Peking Union Med Coll, Peking Union Med Coll Hosp, Dept Resp Dis, Beijing 100730, Peoples R China
2.Peking Univ, Dept Thorac Surg, Peoples Hosp, Beijing 100871, Peoples R China

Recommended Citation:
Zhao, Xiao,Han, Ru-Bing,Zhao, Jing,et al. Comparison of Epidermal Growth Factor Receptor Mutation Statuses in Tissue and Plasma in Stage I-IV Non-Small Cell Lung Cancer Patients[J]. RESPIRATION,2013,85(2):119-125.
Service
Recommend this item
Sava as my favorate item
Show this item's statistics
Export Endnote File
Google Scholar
Similar articles in Google Scholar
[Zhao, Xiao]'s Articles
[Han, Ru-Bing]'s Articles
[Zhao, Jing]'s Articles
CSDL cross search
Similar articles in CSDL Cross Search
[Zhao, Xiao]‘s Articles
[Han, Ru-Bing]‘s Articles
[Zhao, Jing]‘s Articles
Related Copyright Policies
Null
Social Bookmarking
Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit

Items in IR are protected by copyright, with all rights reserved, unless otherwise indicated.

 

 

Valid XHTML 1.0!
Copyright © 2007-2017  北京大学医学部 - Feedback
Powered by CSpace